111732
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
动脉灌注化疗联合栓塞治疗复发/转移性软组织肉瘤的可行性及耐受性：一项回顾性探索性研究
Authors Li J, Liu R, Zhu BR , Wang DL, Zhou JM, Yang WW, Wang MQ
Received 2 June 2025
Accepted for publication 30 September 2025
Published 16 October 2025 Volume 2025:19 Pages 9399—9413
DOI https://doi.org/10.2147/DDDT.S538212
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Anastasios Lymperopoulos
Jing Li,1,* Rui Liu,2,* Bao-Rang Zhu,1 Dai-Lian Wang,1 Jie-Min Zhou,1 Wu-Wei Yang,1 Mao-Qiang Wang1
1Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing, 100071, People’s Republic of China; 2Department of Vascular Intervention, Aerospace Center Hospital, Beijing, 100076, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Wu-Wei Yang, Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing, 100071, People’s Republic of China, Tel +8618501270097, Email yww307@163.com Mao-Qiang Wang, Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing, 100071, People’s Republic of China, Email wangmq202507@163.com
Objective: This study aimed to evaluate the feasibility and tolerability of arterial infusion chemotherapy embolization (AICE) in treating recurrent/metastatic soft tissue sarcoma (STS) and to explore relevant prognostic factors to tailor future individualized treatment.
Methods: A total of 113 patients with recurrent/metastatic STS treated with AICE at the Fifth Medical Center of the PLA General Hospital were included in this retrospective study. The primary outcomes were progression-free survival (PFS) and overall survival (OS). Kaplan–Meier survival curves were adopted and univariate and multivariate analyses were conducted using the Cox proportional hazards model to evaluate prognostic factors. Treatment-related adverse events (TRAEs) were graded according to the Society of Interventional Radiology (SIR) standards.
Results: Among the 113 patients, the median OS was 19.0 months (95% CI: 12.8– 25.3) with 2-year OS rates of 45.1%. The median PFS was 11.0 months (95% CI: 8.6– 13.4) with 2-year PFS rates of 25.7%. Objective response rate (ORR) was 37.2% (95% CI: 28.3%– 46.8%) and disease control rate (DCR) was 76.1% (95% CI: 67.1%– 83.6%). Univariate analysis revealed that tumor size, presence of distant metastasis, number of postoperative treatment regimens, pathological differentiation and neutrophil-to-lymphocyte ratio (NLR) were significantly associated with OS and PFS (P< 0.05). Multivariate Cox analysis confirmed that tumor size, distant metastasis, number of postoperative treatment regimens, pathological differentiation and short-term efficacy were independent prognostic factors for OS (P< 0.05). The most common TRAEs were pain (23.0%), transient bone marrow suppression (15.0%) and postoperative fever (6.2%). No severe or fatal adverse reactions and treatment-related mortalities were observed, demonstrating superior tolerability.
Conclusion: AICE might be a feasible and well-tolerated treatment for recurrent/metastatic STS, effectively controlling disease progression and improving survival outcomes in this retrospective cohort. Further multicenter, large-scale prospective studies were needed to validate these findings and explore the combination of AICE with immunotherapy or targeted therapy to optimize treatment strategy for STS.
Keywords: soft tissue sarcoma, arterial infusion chemotherapy embolization, efficacy, safety, prognosis
1Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing, 100071, People’s Republic of China; 2Department of Vascular Intervention, Aerospace Center Hospital, Beijing, 100076, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Wu-Wei Yang, Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing, 100071, People’s Republic of China, Tel +8618501270097, Email yww307@163.com Mao-Qiang Wang, Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing, 100071, People’s Republic of China, Email wangmq202507@163.com
Objective: This study aimed to evaluate the feasibility and tolerability of arterial infusion chemotherapy embolization (AICE) in treating recurrent/metastatic soft tissue sarcoma (STS) and to explore relevant prognostic factors to tailor future individualized treatment.
Methods: A total of 113 patients with recurrent/metastatic STS treated with AICE at the Fifth Medical Center of the PLA General Hospital were included in this retrospective study. The primary outcomes were progression-free survival (PFS) and overall survival (OS). Kaplan–Meier survival curves were adopted and univariate and multivariate analyses were conducted using the Cox proportional hazards model to evaluate prognostic factors. Treatment-related adverse events (TRAEs) were graded according to the Society of Interventional Radiology (SIR) standards.
Results: Among the 113 patients, the median OS was 19.0 months (95% CI: 12.8– 25.3) with 2-year OS rates of 45.1%. The median PFS was 11.0 months (95% CI: 8.6– 13.4) with 2-year PFS rates of 25.7%. Objective response rate (ORR) was 37.2% (95% CI: 28.3%– 46.8%) and disease control rate (DCR) was 76.1% (95% CI: 67.1%– 83.6%). Univariate analysis revealed that tumor size, presence of distant metastasis, number of postoperative treatment regimens, pathological differentiation and neutrophil-to-lymphocyte ratio (NLR) were significantly associated with OS and PFS (P< 0.05). Multivariate Cox analysis confirmed that tumor size, distant metastasis, number of postoperative treatment regimens, pathological differentiation and short-term efficacy were independent prognostic factors for OS (P< 0.05). The most common TRAEs were pain (23.0%), transient bone marrow suppression (15.0%) and postoperative fever (6.2%). No severe or fatal adverse reactions and treatment-related mortalities were observed, demonstrating superior tolerability.
Conclusion: AICE might be a feasible and well-tolerated treatment for recurrent/metastatic STS, effectively controlling disease progression and improving survival outcomes in this retrospective cohort. Further multicenter, large-scale prospective studies were needed to validate these findings and explore the combination of AICE with immunotherapy or targeted therapy to optimize treatment strategy for STS.
Keywords: soft tissue sarcoma, arterial infusion chemotherapy embolization, efficacy, safety, prognosis